First-of-its-Kind stem cell trial aims to halt debilitating MS
NCT ID NCT06592703
Summary
This is a small, early-stage study to test the safety of a new cell therapy for a severe form of multiple sclerosis (MS). Researchers will give participants three injections of donor-derived stem cells into the spinal fluid over several months. The main goal is to see if the treatment is safe, while also checking if it might slow the worsening of disability in people with primary progressive MS.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP Henri Mondor
ACTIVE_NOT_RECRUITINGCréteil, France
-
CHU Rennes
RECRUITINGRennes, France
Contact
Contact
Conditions
Explore the condition pages connected to this study.